Phase II study of intravesical instillation of EOquin [apaziquone] in high risk superficial bladder cancer
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2012
At a glance
- Drugs Apaziquone (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 Jun 2012 Actual end date (1 Dec 2009) added as reported by ClinicalTrials.gov.
- 19 Jun 2008 Results data from this trial were presented to the US FDA in early 2006, according to a Spectrum Pharmaceuticals media release (9090349).